Peptic Ulcer Drugs Market | Continues to Expand | Development | Future Challenges
The Peptic Ulcer Drugs Market analysis report speaks about the growth rate till 2027 manufacturing process, Growth, key factors driving this market with sales, revenue, and price analysis of lead manufacturers, distributors, traders and dealers of Peptic Ulcer Drugs.
Coherent Market Insights always aims at offering their clients an in-depth analysis and the best research material of the various market. The “Peptic Ulcer Drugs Market projected to develop with growing expansion prospects”. The Peptic Ulcer Drugs Market report presents a calculated opinion of the analyzed Peptic Ulcer Drugs Market data. It explains various opportunities dedicated to different industries, suppliers, organizations, and associations offering various products and services such as offering them precise guidance for their expansion in the competition for reliable services to consumers. The report provides detailed information on key competitors in the market and on emerging companies with significant market share based on demand, revenue, sales, high-quality product manufacturers, and service providers.
The prominent players in the Peptic Ulcer Drugs Market are Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Abbott Laboratories, AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline plc.
Drivers
Over the forecast period, the global peptic ulcer drugs market is expected to rise due to an increasing preference for peptic ulcer drugs over surgical approaches for the treatment of PUD. This is due to the complexities of surgical treatment and peptic ulcer post-surgical complications.
Opportunities
Players in the global peptic ulcer drugs market should foresee attractive growth prospects in the developing healthcare sector in emerging markets. The healthcare sector in India is projected to cross US$ 372 billion by 2022, according to the India Brand Equity Foundation, owing to rising health consciousness, disposable income, and access to health insurance.
Restraints
Antibiotic resistance among helicobacter pylori strains is expected to stifle growth of the global peptic ulcer drugs market to some extent. Rising research and development activities on novel therapeutics for developing newer strains is expected to help the market expansion.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/3246
Key Takeaways
The Gastroesophageal Reflux Disease segment of the global peptic ulcer drugs market was worth US$ 18,185.7 million in 2018, and is projected to develop at a CAGR of 2.9 percent to US$ 23,492.2 million by 2027. The incidence and prevalence of gastroesophageal reflux disease in developed economies are due to the segment’s development.
In terms of sales, the hospital pharmacies segment dominated the global peptic ulcer drugs market in 2018, contributing about 48.1 percent of the market, followed by retail pharmacies and drug stores. During the forecast period, the segment’s development is expected to be aided by an increasing preference for peptic ulcer medications over surgical methods.
Market Trends
In patients with cardiovascular and inflammatory disorders, long-term aspirin use can increase the risk of gastrointestinal bleeding. As a result of this situation, proton pump inhibitors are now prescribed alongside aspirin.
Furthermore, due to their pharmacodynamic properties, H2 antagonists are becoming more popular in North America. Due to their rapid onset of action and long-lasting anti-secretory activity, H2 blockers are successful in the treatment of PUD.
Competitive Landscape
Key companies contributing in the global peptic ulcer drugs market are RedHill Biopharma, Novitium Pharma LLC, Takeda Pharmaceutical Co., Ltd., Abbott Laboratories, Eisai Co. Ltd., Daewoong Pharmaceutical Co., Ltd., GlaxoSmithKline plc., Yuhan Corporation, AstraZeneca plc., Pfizer Inc., Boehringer Ingelheim GmbH, and Cadila Healthcare Ltd.
Key Developments
Meridian Bioscience, Inc. sent Curian and the Curian HpSA assay to the US FDA for approval in November 2019. Using fluorescent lateral flow technology, the platform and assay was developed to directly identify Helicobacter pylori antigens in human stool.
Sihuan Pharmaceutical Holdings Group Ltd. reported in April 2019 that patient recruitment for its proprietary novel digestive system medication, Anaprazole Sodium, for a Phase II clinical trial in China has been completed early.
Main points in Peptic Ulcer Drugs Market Report Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Peptic Ulcer Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Peptic Ulcer Drugs Industry Impact
Chapter 2 Global Peptic Ulcer Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Peptic Ulcer Drugs (Volume and Value) by Type
2.3 Global Peptic Ulcer Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Peptic Ulcer Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Peptic Ulcer Drugs Market Analysis
Chapter 6 East Asia Peptic Ulcer Drugs Market Analysis
Chapter 7 Europe Peptic Ulcer Drugs Market Analysis
Chapter 8 South Asia Peptic Ulcer Drugs Market Analysis
Chapter 9 Southeast Asia Peptic Ulcer Drugs Market Analysis
Chapter 10 Middle East Peptic Ulcer Drugs Market Analysis
Chapter 11 Africa Peptic Ulcer Drugs Market Analysis
Chapter 12 Oceania Peptic Ulcer Drugs Market Analysis
Chapter 13 South America Peptic Ulcer Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Peptic Ulcer Drugs Business
Chapter 15 Global Peptic Ulcer Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
